CONNECT WITH US
HealthTech

HealthTech

Cheap drug may prevent second stroke by lowering blood pressure

Medical Xpress logo

Published on

Add as a preferred source on Google
Cheap drug may prevent second stroke by lowering blood pressure

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

It's vital to lower blood pressure after a stroke, so the survivor doesn't suffer another as they recover. And it appears this safety measure can be achieved on the cheap, a new study says.

An inexpensive diuretic drug helped stroke survivors reach their recommended blood pressure nearly twice as often as others receiving usual post-stroke care, researchers reported at a recent meeting of the American Heart Association (AHA) in Chicago.

The drug, spironolactone, costs as little as $6 for a month's supply, according to Drugs.com.

"Lowering blood pressure is the most important step in preventing another stroke, yet many survivors struggle to reach recommended blood pressure targets after a stroke," said co-lead researcher Dr. Jordana Cohen, an associate professor of medicine and epidemiology at the University of Pennsylvania.

"We were surprised to see that blood pressure dropped twice as much as we expected," Cohen said in a news release.

Nearly 1 in 4 stroke survivors will have another stroke, but up to 80% of strokes can be prevented, researchers said in background notes.

Spironolactone lowers blood pressure by blocking aldosterone, a hormone that signals the kidneys to hold on to salt and water, researchers said. As a result, people urinate more often, reducing the amount of fluid in their bodies. A diuretic like this might be referred to as a "water pill."

S. hospitals recruited 160 adults with an average age of 63 who'd survived a stroke.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.